ArticleBMC infectious diseases2022
Venous thromboembolism in COVID-19 patients and prediction model: a multicenter cohort study.
Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Thoracolumbar spine surgery in the post-pandemic era: a national retrospective analysis of thrombotic complications, vaccination status, and prior hospitalization with COVID-19.Asian spine journal · 2026Article
- Hematological Markers in Thromboembolic Events: A Comparative Study of COVID-19 and Non-COVID-19 Hospitalized Patients.Journal of clinical medicine · 2025Article
- Associations of blood pressure in the third trimester and risk of venous thromboembolism postpartum.MedComm · 2024Article
- Article
- The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications.Heart (British Cardiac Society) · 2024Article
- Venous Thromboembolism in Patients Hospitalized for COVID-19 in a Non-Intensive Care Unit.Journal of clinical medicine · 2024Article
- Inflammation and Venous Thromboembolism in Hospitalized Patients with COVID-19.Diagnostics (Basel, Switzerland) · 2023Article
- Predictors of pulmonary embolism in hospitalized patients with COVID-19.Thrombosis journal · 2023Article
- Outcomes of viral myocarditis in patients with and without COVID-19: a nationwide analysis from the United States.Annals of medicine and surgery (2012) · 2023Article
- Article
- COVID-19 and the Response to Antiplatelet Therapy.Journal of clinical medicine · 2023Review
- SARS-CoV-2 spike protein promotes inflammatory cytokine activation and aggravates rheumatoid arthritis.Cell communication and signaling : CCS · 2023Article
- Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study).BMJ medicine · 2023Article
- SARS-COV-ATE risk assessment model for arterial thromboembolism in COVID-19.Scientific reports · 2022Article
- Increased Susceptibility for Thromboembolic Events versus High Bleeding Risk Associated with COVID-19.Microorganisms · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with COVID-19 infection are commonly reported to have an increased risk of venous thrombosis. The choice of anti-thrombotic agents and doses are currently being studied in randomized controlled trials and retrospective studies. There exists a need for individualized risk stratification of venous thromboembolism (VTE) to assist clinicians in decision-making on anticoagulation. We sought to identify the risk factors of VTE in COVID-19 patients, which could help physicians in the prevention, early identification, and management of VTE in hospitalized COVID-19 patients and improve clinical outcomes in these patients.
methodThis is a multicenter, retrospective database of four main health systems in Southeast Michigan, United States. We compiled comprehensive data for adult COVID-19 patients who were admitted between 1st March 2020 and 31st December 2020. Four models, including the random forest, multiple logistic regression, multilinear regression, and decision trees, were built on the primary outcome of in-hospital acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and tested for performance. The study also reported hospital length of stay (LOS) and intensive care unit (ICU) LOS in the VTE and the non-VTE patients. Four models were assessed using the area under the receiver operating characteristic curve and confusion matrix.
resultsThe cohort included 3531 admissions, 3526 had discharge diagnoses, and 6.68% of patients developed acute VTE (N = 236). VTE group had a longer hospital and ICU LOS than the non-VTE group (hospital LOS 12.2 days vs. 8.8 days, p < 0.001; ICU LOS 3.8 days vs. 1.9 days, p < 0.001). 9.8% of patients in the VTE group required more advanced oxygen support, compared to 2.7% of patients in the non-VTE group (p < 0.001). Among all four models, the random forest model had the best performance. The model suggested that blood pressure, electrolytes, renal function, hepatic enzymes, and inflammatory markers were predictors for in-hospital VTE in COVID-19 patients.
conclusionsPatients with COVID-19 have a high risk for VTE, and patients who developed VTE had a prolonged hospital and ICU stay. This random forest prediction model for VTE in COVID-19 patients identifies predictors which could aid physicians in making a clinical judgment on empirical dosages of anticoagulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.